Matinas BioPharma Holdings (MTNB) Total Current Liabilities (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Total Current Liabilities data on file, last reported at $2.1 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $2.1 million, down 5.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 million (down 5.72% YoY), and the FY2025 annual result was $1.5 million, down 45.12% from the prior year.
• Total Current Liabilities grew to $2.1 million in Q1 2026 per MTNB's latest filing, from $1.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $5.4 million in Q2 2022 and troughed at $1.5 million in Q4 2025.
• A 5-year average of $2.8 million and a median of $2.4 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 69.65% in 2022, then plunged 51.9% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $4.3 million in 2022, then sank by 38.82% to $2.6 million in 2023, then rose by 1.68% to $2.7 million in 2024, then plunged by 45.12% to $1.5 million in 2025, then jumped by 45.32% to $2.1 million in 2026.
• Business Quant data shows MTNB's Total Current Liabilities at $2.1 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.